TRACON Pharmaceuticals, Inc. to Present Three First-in-Class Oncology Therapeutics (TRC105, TRC102, and TRC093) at the American Society of Clinical Oncology 2010 Annual Meeting

SAN DIEGO, May 19, 2010 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL. Each of these three cancer therapies targets a novel pathway with potential for broad application to a wide variety of cancer types.